Yakangbo

Established in 2004, Yakangbo Lianhe originates from Tsinghua University and is one of the first national high-tech enterprises in China dedicated to providing one-stop molecular diagnostic products and testing services for "precision oncology diagnostics."

Yakangbo Lianhe holds qualifications for the production and operation of related in vitro diagnostic products, as well as third-party independent medical laboratory testing. It offers diagnostic products and testing services covering the entire cancer care cycle, including early cancer screening, companion diagnostics, medication monitoring, and post-surgical prognosis.

The company's R&D center is located in Beijing, where it has developed and manufactured over 50 molecular biology testing products. It operates three medical testing laboratories in Beijing, Hangzhou, and Jiaxing, with a service network spanning 22 provinces and cities nationwide. Leveraging its strong R&D capabilities and technological advantages, the company has established precision medicine business collaborations with nearly 1,000 Class III Grade A hospitals and specialized cancer hospitals nationwide. It has supported and participated in over 30 large-scale medical research projects and has earned high recognition from hundreds of domestic specialized oncology institutions.

The company's testing laboratories strictly adhere to ISO15189:2012 and CAP standards, maintaining a comprehensive quality management system. They have obtained CAP accreditation from the College of American Pathologists and actively participate in external proficiency testing programs, achieving perfect scores in multiple rounds of high-throughput sequencing external quality assessments organized by the National Center for Clinical Laboratories (NCCL) in 2018, 2019, and 2020, as well as outstanding results in various assessments organized by the European Molecular Genetics Quality Network (EMQN).